SpringerLink
Log in

Novel and Investigational Therapies in Acute Myeloid Leukemia

  • Chapter
  • First Online:
Acute Leukemias

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

  • 1040 Accesses

Abstract

Acute myeloid leukemia (AML) is classified into four broad categories in the revised World Health Organization classification for myeloid neoplasms; AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related myeloid neoplasms, and AML not otherwise specified. With better understanding of the disease biology, many novel agents have been developed and are now incorporated in the treatment paradigm for AML. We summarize in this chapter the molecular landscape of AML, novel therapies that have received regulatory approval, as well as selected investigational agents that are in early stages of development (first-in human trials) and focus on those in later stages of development. Each section will emphasize selected investigational agents based on their mechanism of action or targeted pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 58.84
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 58.84
Price includes VAT (Germany)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
EUR 80.24
Price includes VAT (Germany)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381:484. https://doi.org/10.1016/S0140-6736(12)61727-9.

    Article  PubMed  Google Scholar 

  2. National Cancer Institute (2008) Bethesda MD. SEER cancer stat facts: acute myeloid leukemia. https://seer.cancer.gov/statfacts/html/amyl.html

  3. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424. https://doi.org/10.1182/blood-2016-08-733196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018a;378(25):2386–98. https://doi.org/10.1056/NEJMoa1716984.

    Article  CAS  PubMed  Google Scholar 

  5. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7. https://doi.org/10.1182/blood-2018-08-868752.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–96. https://doi.org/10.1016/S1470-2045(14)70281-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lancet JE, Uy GL, Cortes JE, et al. Cpx-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684. https://doi.org/10.1200/JCO.2017.77.6112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–31. https://doi.org/10.1182/blood-2017-04-779405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–64. https://doi.org/10.1056/NEJMoa1614359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Al-Issa K, Nazha A. Molecular landscape in acute myeloid leukemia: where do we stand in 2016. Cancer Biol Med. 2016;13(4):474–82. https://doi.org/10.20892/j.issn.2095-3941.2016.0061.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–84. https://doi.org/10.1038/nm.3788.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29–41. https://doi.org/10.1182/blood-2015-07-604496.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Cancer Genome Atlas Research N, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–74. https://doi.org/10.1056/NEJMoa1301689.

    Article  CAS  Google Scholar 

  14. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367–76. https://doi.org/10.1182/blood-2014-11-610543.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Nazha A, Zarzour A, Al-Issa K, et al. The complexity of interpreting genomic data in patients with acute myeloid leukemia. Blood Cancer J. 2016;6(12):e510. https://doi.org/10.1038/bcj.2016.115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood. 2017;130:2373. https://doi.org/10.1182/blood-2017-09-797712.

    Article  CAS  PubMed  Google Scholar 

  17. Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 2017;18(8):1061–75. https://doi.org/10.1016/S1470-2045(17)30416-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wei AH, Strickland SA, Hou J-Z, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–84. https://doi.org/10.1200/JCO.18.01600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Feldman EJ, Lancet JE, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29:979. https://doi.org/10.1200/JCO.2010.30.5961.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cortes JE, Goldberg SL, Feldman EJ, et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015;121:234. https://doi.org/10.1002/cncr.28974.

    Article  CAS  PubMed  Google Scholar 

  21. Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123:3239. https://doi.org/10.1182/blood-2013-12-540971.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–9. https://doi.org/10.1182/blood-2015-01-621664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–7. https://doi.org/10.1200/JCO.2011.38.9429.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kantarjian HM, Roboz GJ, Kropf PL, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017;18:1317. https://doi.org/10.1016/S1470-2045(17)30576-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Roboz GJ, Kantarjian HM, Yee KWL, et al. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 2018;124:325. https://doi.org/10.1002/cncr.31138.

    Article  CAS  PubMed  Google Scholar 

  26. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008;269(1):7–17. https://doi.org/10.1016/j.canlet.2008.03.037.

    Article  CAS  PubMed  Google Scholar 

  27. Zhou L, Ruvolo VR, McQueen T, et al. HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia. 2013;27:1358. https://doi.org/10.1038/leu.2012.366.

    Article  CAS  PubMed  Google Scholar 

  28. Abaza YM, Kadia TM, Jabbour EJ, et al. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017; https://doi.org/10.1002/cncr.30949.

  29. Garcia-Manero G, Montalban-Bravo G, Berdeja JG, et al. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer. 2017;123(6):994–1002. https://doi.org/10.1002/cncr.30533.

    Article  CAS  PubMed  Google Scholar 

  30. Garcia-Manero G, Atallah E, Khaled SK, et al. Final results from a phase 2 study of pracinostat in combination with azacitidine in elderly patients with acute myeloid leukemia (AML). Blood. 2015;126(23):453. http://www.bloodjournal.org/content/126/23/453.abstract

    Article  Google Scholar 

  31. Garcia-Manero G, Abaza Y, Takahashi K, et al. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019;3(4):508–18. https://doi.org/10.1182/bloodadvances.2018027409.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. https://doi.org/10.1182/blood-2016-08-733196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379:1508. https://doi.org/10.1016/S0140-6736(12)60485-1.

    Article  CAS  PubMed  Google Scholar 

  34. Castaigne S, Pautas C, Terré C, et al. Final analysis of the ALFA 0701 study. Blood. 2014;124:376.

    Article  Google Scholar 

  35. Fathi AT, Erba HP, Lancet JE, et al (2016) Vadastuximab talirine plus hypomethylating agents: a well-tolerated regimen with high remission rate in frontline older patients with acute myeloid leukemia (AML). In: Blood Conf 58th Annu Meet Am Soc Hematol ASH 2016 United States Conf start 20161203 Conf end 20161206

    Google Scholar 

  36. Kovacsovics TJ, Advani AS, Faderl S, et al. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood. 2018;132:1125. https://doi.org/10.1182/blood-2018-03-841171.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Stein EM, Walter RB, Erba HP, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018;131:387. https://doi.org/10.1182/blood-2017-06-789800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Walter RB. Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opin Investig Drugs. 2018;27:339. https://doi.org/10.1080/13543784.2018.1452911.

    Article  CAS  PubMed  Google Scholar 

  39. Ravandi F, Stein AS, Kantarjian HM, et al. A phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE®) antibody construct, in relapsed/refractory acute myeloid leukemia (R/R AML). Blood. 2018;132(Suppl 1):25. https://doi.org/10.1182/blood-2018-99-109762.

    Article  Google Scholar 

  40. Ochsenbein AF, Riether C, Bacher U, et al. Argx-110 targeting CD70, in combination with azacitidine, shows favorable safety profile and promising anti-leukemia activity in newly diagnosed AML patients in an ongoing phase 1/2 clinical trial. Blood. 2018;132(Suppl 1):2680. https://doi.org/10.1182/blood-2018-99-118302.

    Article  Google Scholar 

  41. Röllig C, Serve H, Hüttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16:1691. https://doi.org/10.1016/S1470-2045(15)00362-9.

    Article  CAS  PubMed  Google Scholar 

  42. Serve H, Brunnberg U, Ottmann O, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013;31:3110. https://doi.org/10.1200/JCO.2012.46.4990.

    Article  CAS  PubMed  Google Scholar 

  43. Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012;26:2061. https://doi.org/10.1038/leu.2012.115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Cortes JE, Khaled SK, Martinelli G, et al. Efficacy and safety of single-agent quizartinib (Q), a potent and selective FLT3 inhibitor (FLT3i), in patients (pts) with FLT3-internal tandem duplication (FLT3-ITD)-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML) enrolled in the global, phase 3, randomized controlled quantum-R trial. Blood. 2018;132(Suppl 1):563. https://doi.org/10.1182/blood-2018-99-110439.

    Article  Google Scholar 

  45. Lee LY, Hernandez D, Rajkhowa T, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2017;129:257. https://doi.org/10.1182/blood-2016-10-745133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Perl AE, Martinelli G, Cortes JE et al (2019) Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the Phase III ADMIRAL trial. Present 2019 AACR Annu Meet March 29 to April 3, 2019, Atlanta, GA Abstr CTPL04

    Google Scholar 

  47. Weisberg E, Sattler M, Ray A, Griffin JD. Drug resistance in mutant FLT3-positive AML. Oncogene. 2010;29:5120. https://doi.org/10.1038/onc.2010.273.

    Article  CAS  PubMed  Google Scholar 

  48. Zimmerman EI, Turner DC, Buaboonnam J, et al. Crenolanib is active against models of drug-resistant FLT3-ITD – positive acute myeloid leukemia. Blood. 2013;122:3607. https://doi.org/10.1182/blood-2013-07-513044.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Wang ES, Stone RM, Tallman MS, Walter RB, Eckardt JR, Collins R. Crenolanib, a type I FLT3 TKI, can be safely combined with cytarabine and anthracycline induction chemotherapy and results in high response rates in patients with newly diagnosed FLT3 mutant acute myeloid leukemia (AML). Blood. 2016;128(22):1071. http://www.bloodjournal.org/content/128/22/1071.abstract

    Article  Google Scholar 

  50. DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90(8):732–6. https://doi.org/10.1002/ajh.24072.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31:272. https://doi.org/10.1038/leu.2016.275.

    Article  CAS  PubMed  Google Scholar 

  52. Nassereddine S, Lap CJ, Haroun F, Tabbara I. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. Ann Hematol. 2017;96(12):1983–91. https://doi.org/10.1007/s00277-017-3161-0.

    Article  CAS  PubMed  Google Scholar 

  53. Papaemmanuil E, Döhner H, Campbell PJ. Genomic classification in acute myeloid leukemia. N Engl J Med. 2016;375:900. https://doi.org/10.1056/NEJMc1608739.

    Article  PubMed  Google Scholar 

  54. DiNardo CD, de Botton S, Stein EM, et al. Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of mutant IDH1. Blood. 2016;128:1070.

    Article  Google Scholar 

  55. Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362–75. https://doi.org/10.1158/2159-8290.CD-13-0609.

    Article  CAS  PubMed  Google Scholar 

  56. Pullarkat VA, Newman EM. BCL2 inhibition by venetoclax: targeting the Achilles’ heel of the acute myeloid leukemia stem cell? Cancer Discov. 2016;6(10):1082–3. 6/10/1082 [pii]

    Article  CAS  PubMed  Google Scholar 

  57. Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–17. 2159-8290.CD-16-0313 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Wei A, Strickland SA, Roboz GJ, et al. Phase 1/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes. Blood. 2017;130(Suppl 1):890.

    Google Scholar 

  59. DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018b;19:216. https://doi.org/10.1016/S1470-2045(18)30010-X.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Amanda Mendelsohn at the Center for Medical Art & Photography, at Cleveland Clinic, for her efforts in creating the figure in this chapter.

Author information

Authors and Affiliations

  1. Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

    Yazan F. Madanat & Aziz Nazha

Authors
  1. Yazan F. Madanat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aziz Nazha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aziz Nazha .

Editor information

Editors and Affiliations

  1. Reno, NV, USA

    Stefan H. Faderl

  2. Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX, USA

    Hagop M. Kantarjian

  3. Clinical Research Division, Fred Hutch, Seattle, WA, USA

    Elihu Estey

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Madanat, Y.F., Nazha, A. (2021). Novel and Investigational Therapies in Acute Myeloid Leukemia. In: Faderl, S.H., Kantarjian, H.M., Estey, E. (eds) Acute Leukemias. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-53633-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53633-6_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53632-9

  • Online ISBN: 978-3-030-53633-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation